Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Participant baseline characteristics at 5-year follow-upCharacteristicDiabetes (n = 152 497)Hypertension (n = 122 041)CV (n = 122 666)CHD (n = 120 057)CVD mortality (n = 120 238)All-cause mortality (n = 120 238)Age (years), median (IQR)57 (49 to 63)56 (48 to 62)56 (49 to 62)56 (48 to 62)56 (48 to 62)56 (48 to 62)Gender, n (%)Male76 948 (50.5)53 219 (43.6)53 587 (43.7)51 670 (43.0)51 813 (43.1)51 813 (43.1)Female75 549 (49.5)68 822 (56.4)69 079 (56.3)68 387 (57.0)68 425 (56.9)68 425 (56.9)Ethnic group, n (%)White146 057 (96.2)116 665 (96.0)117 206 (96.0)115 227 (96.3)115 399 (96.3)115 399 (96.3)Ethnic minority5755 (3.8)4811 (4.0)4861 (4.0)4494 (3.7)4501 (3.7)4501 (3.7)Apolipoprotein A (g/L), mean (s.d.)1.5 (0.3)1.5 (0.3)1.5 (0.3)1.5 (0.3)1.5 (0.3)1.5 (0.3)Apolipoprotein B (g/L), mean (s.d.)1.0 (0.2)1.0 (0.2)1.0 (0.2)1.0 (0.3)1.1 (0.2)1.1 (0.2)Haemoglobin A1c (mmol/mol), median (IQR)34.9 (32.5 to 37.2)34.7 (32.4 to 37.1)34.7 (32.4 to 37.1)34.6 (32.3 to 37.0)34.6 (32.3 to 37.0)34.6 (32.3 to 37.0)BMI (kg/m2), median (IQR)26.5 (24.0 to 29.5)26.1 (23.7 to 28.9)26.1 (23.7 to 28.9)26.1 (23.7 to 28.9)26.0 (23.7 to 28.9)26.0 (23.7 to 28.9)WHR, median (IQR)0.87 (0.80 to 0.94)0.86 (0.79 to 0.92)0.86 (0.79 to 0.92)0.85 (0.79 to 0.92)0.86 (0.79 to 0.92)0.86 (0.79 to 0.92)Triglycerides (mmol/L), median (IQR)1.46 (1.03 to 2.12)1.47 (1.00 to 2.04)1.41 (1.00 to 2.04)1.4 (1.0 to 2.0)1.40 (1.0 to 2.0)1.40 (1.0 to 2.0)Vitamin D (nmol/L), median (IQR)46.9 (32.5 to 62.4)47.0 (32.5 to 62.4)46.9 (32.5 to 62.4)47.1 (32.6 to 62.5)47.1 (32.6 to 62.5)47.1 (32.6 to 62.5)Long-standing illness, n (%)No107 350 (72.1)90 123 (75.5)90 458 (75.4)89 751 (76.3)89 843 (76.2)89 843 (76.2)Yes41 552 (27.929 277 (24.5)29 515 (24.6)27 955 (23.7)28 040 (23.8)28 040 (23.8)Ever smoked, n (%)No61 895 (40.8)51 453 (42.4)51 699 (42.4)50 794 (42.4)50 855 (42.4)50 855 (42.4)Yes89 902 (59.2)70 009 (57.6)70 351 (57.6)68 913 (57.6)69 033 (57.6)69 033 (57.6)Alcohol intake, n (%)Never10 348 (6.8)8439 (6.9)8507 (6.9)8151 (6.8)8168 (6.8)8168 (6.8)Special occasions only15 102 (9.9)12 438 (10.2)12 517 (10.2)12 172 (10.1)12 191 (10.1)12 191 (10.1)1 to 3 times per month16 713 (11.0)13 984 (11.5)14 044 (11.5)13 777 (11.5)13 797 (11.5)13 797 (11.5)Once or twice a week41 117 (27.0)33 446 (27.5)33 616 (27.5)33 026 (27.5)33 069 (27.5)33 069 (27.5)3 to 4 times a week37 419 (24.6)29 725 (24.4)29 842 (24.4)29 409 (24.5)29 450 (24.5)29 450 (24.5)Daily31 456 (20.7)23 718 (19.5)23 818 (19.5)23 455 (19.5)23 495 (10.6)23 495 (10.6)Number of days/week of moderate physical activity, n (%)017 824 (12.3)13 830 (11.9)13 914 (11.9)13 540 (11.8)13 563 (11.8)13 563 (11.8)111 635 (8.0)9408 (8.1)9440 (8.0)9251 (8.1)9261 (8.1)9261 (8.1)2 to 343 323 (29.8)35 167 (30.2)35 312 (30.2)34 718 (30.2)34 762 (30.2)34 762 (30.2)4 to 536 946 (25.4)29 515 (25.4)29 658 (25.4)29 171 (25.4)29 214 (25.4)29 214 (25.4)6 to 735 498 (24.4)28 450 (24.4)28 599 (24.5)28 092 (24.5)28 141 (24.5)28 141 (24.5)Parental history,a n (%)No131 802 (86.4)86 802 (71.1)110 316 (89.9)98 445 (82.0)47 156 (39.2)47 156 (39.2)Yes20 695 (13.6)35 239 (28.9)12 350 (10.1)21 612 (18.0)73 082 (60.8)73 082 (60.8)Type of accommodation, n (%)House138 745 (91.4)111 365 (91.6)111 897 (91.6)109 821 (91.7)109 977 (91.7)109 977 (91.7)Flat/apartment12 765 (8.4)9927 (8.2)9987 (8.2)9695 (8.1)9719 (8.1)9719 (8.1)Other359 (0.2)240 (0.2)243 (0.2)234 (0.2)234 (0.2)234 (0.2)Household vehicles, n (%)None10 601 (7.0)8006 (6.6)8067 (6.6)7792 (6.5)7807 (6.5)7807 (6.5)One62 830 (41.5)49 416 (40.8)49 679 (40.8)48 689 (40.8)48 771 (40.8)48 771 (40.8)Two60 717 (40.1)49 560 (40.9)49 777 (40.9)48 944 (41.0)49 010 (50.0)49 010 (50.0)Three or more17 282 (11.4)14 210 (11.7)14 257 (11.7)14 008 (11.7)14 024 (11.7)14 024 (11.7)Employment status, n (%)Paid92 616 (61.3)77 652 (64.3)77 914 (64.2)76 683 (64.4)76 762 (64.4)76 762 (64.4)Retired47 225 (31.3)34 478 (28.5)34 763 (28.6)33 953 (28.5)34 048 (28.5)34 048 (28.5)Unpaid role/student4998 (3.3)4481 (3.7)4492 (3.7)4411 (3.7)4413 (3.7)4413 (3.7)Unable to work3889 (2.6)2477 (2.0)2503 (2.1)2376 (2.0)2379 (2.0)2379 (2.0)Unemployed2266 (1.5)1732 (1.4)1742 (1.4)1660 (1.4)1661 (1.4)1661 (1.4)Educational qualifications, n (%)School level40 258 (31.9)33 019 (32.0)33 146 (40.0)25 863 (25.4)25 885 (25.4)25 885 (25.4)NVQ/HND or equivalent10 650 (8.4)7746 (7.5)7788 (7.5)7589 (7.4)7601 (7.4)7601 (7.4)A level or equivalent16 846 (13.3)13 912 (13.5)13 969 (13.5)20 460 (20.1)20 486 (20.1)20 486 (20.1)University/professional58 631 (46.4)48 591 (47.0)48 781 (47.0)47 990 (47.1)48 055 (47.1)48 055 (47.1)Disability allowance, n (%)No benefits144 265 (95.5)116 671 (96.5)117 185 (96.5)115 148 (96.6)115 307 (96.6)115 307 (96.6)Disability benefits6752 (4.5)4247 (3.5)4306 (3.5)4089 (3.4)4108 (3.4)4108 (3.4)Urban/rural home status, n (%)Rural/small town23 973 (15.9)19 320 (16.0)19 391 (16.0)19 089 (16.0)19 114 (16.0)19 114 (16.0)Urban127 210 (84.1)101 642 (84.0)102 189 (84.0)99 904 (84.0)100 060 (84.0)100 060 (84.0)Household income (£), n (%)<18 00027 504 (20.8)20 304 (19.2)20 449 (19.3)19 866 (19.1)19 904 (19.1)19 904 (19.1)18 000 to 30 99933 938 (25.7)26 450 (25.1)26 582 (25.1)26 045 (25.0)26 088 (25.0)26 088 (25.0)31 000 to 51 99936 104 (27.4)29 593 (28.0)29 698 (28.0)29 268 (28.1)29 300 (28.1)29 300 (28.1)52 000 to 100 00027 653 (20.9)23 391 (22.2)23 465 (22.1)23 156 (22.2)23 179 (22.2)23 179 (22.2)>100 0006825 (5.2)5855 (5.5)5873 (5.5)5781 (5.6)5792 (5.6)5792 (5.6)CV, cerebrovascular disease; CHD, coronary heart disease; CVD, cardiovascular disease; IQR, interquartile range; BMI, body mass index; WHR, waist/hip ratio; NVQ/HND, National Vocational Qualification/Higher National Diploma.Parental history of outcome, for mortality outcomes this is parental history of cardiometabolic and vascular disease.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Antidepressant use and risk of adverse outcomes: population-based cohort study

Source: Article title.

UK Biobank recruited approximately 500 000 participants aged 40 to 69 years between 2006 and 2010.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Antidepressant use and risk of adverse outcomes: population-based cohort study

Cohort study · BJPsych Open · 2022

Original publication title

Antidepressant use and risk of adverse outcomes: population-based cohort study

Narinder Bansal; Mohammed Hudda; Rupert A. Payne; Daniel J. Smith; David Kessler; Nicola Wiles

© The Author(s) 2022

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Our findings indicate an association between long-term antidepressant usage and elevated risks of CHD, CVD mortality and all-cause mortality. Further research is needed to assess whether the observed associations are causal, and elucidate the underlying mechanisms.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

This study aimed to investigate the association between antidepressant use and adverse events.

Source: Aims

Abstract: What methods does the paper describe?

The study cohort consisted of UK Biobank participants whose data was linked to primary care records (N = 222 121). We assessed the association between antidepressant use by drug class (selective serotonin reuptake inhibitors (SSRIs) and ‘other’) and four morbidity (diabetes, hypertension, coronary heart disease (CHD), cerebrovascular disease (CV)) and two mortality (cardiovascular disease (CVD) and all-cause) outcomes, using Cox's proportional hazards model at 5: and 10-year follow-up.

Source: Method

Abstract: Results

SSRI treatment was associated with decreased risk of diabetes at 5 years (hazard ratio 0.64, 95% CI 0.49 to 0.83) and 10 years (hazard ratio 0.68, 95% CI 0.53 to 0.87), and hypertension at 10 years (hazard ratio 0.77, 95% CI 0.66 to 0.89). At 10-year follow-up, SSRI treatment was associated with increased risks of CV (hazard ratio 1.34, 95% CI 1.02 to 1.77), CVD mortality (hazard ratio 1.87, 95% CI 1.38 to 2.53) and all-cause mortality (hazard ratio 1.73, 95% CI 1.48 to 2.03), and ‘other’ class treatment was associated with increased risk of CHD (hazard ratio 1.99, 95% CI 1.31 to 3.01), CVD (hazard ratio 1.86, 95% CI 1.10 to 3.15) and all-cause mortality (hazard ratio 2.20, 95% CI 1.71 to 2.84).

Source: Results

Abstract: Conclusions

Our findings indicate an association between long-term antidepressant usage and elevated risks of CHD, CVD mortality and all-cause mortality. Further research is needed to assess whether the observed associations are causal, and elucidate the underlying mechanisms.

Source: Conclusions
Authors’ abstract

Background

Antidepressants are one of the most widely prescribed drugs in the global north. However, little is known about the health consequences of long-term treatment.

Aims

This study aimed to investigate the association between antidepressant use and adverse events.

Method

The study cohort consisted of UK Biobank participants whose data was linked to primary care records (N = 222 121). We assessed the association between antidepressant use by drug class (selective serotonin reuptake inhibitors (SSRIs) and ‘other’) and four morbidity (diabetes, hypertension, coronary heart disease (CHD), cerebrovascular disease (CV)) and two mortality (cardiovascular disease (CVD) and all-cause) outcomes, using Cox's proportional hazards model at 5: and 10-year follow-up.

Results

SSRI treatment was associated with decreased risk of diabetes at 5 years (hazard ratio 0.64, 95% CI 0.49 to 0.83) and 10 years (hazard ratio 0.68, 95% CI 0.53 to 0.87), and hypertension at 10 years (hazard ratio 0.77, 95% CI 0.66 to 0.89). At 10-year follow-up, SSRI treatment was associated with increased risks of CV (hazard ratio 1.34, 95% CI 1.02 to 1.77), CVD mortality (hazard ratio 1.87, 95% CI 1.38 to 2.53) and all-cause mortality (hazard ratio 1.73, 95% CI 1.48 to 2.03), and ‘other’ class treatment was associated with increased risk of CHD (hazard ratio 1.99, 95% CI 1.31 to 3.01), CVD (hazard ratio 1.86, 95% CI 1.10 to 3.15) and all-cause mortality (hazard ratio 2.20, 95% CI 1.71 to 2.84).

Conclusions

Our findings indicate an association between long-term antidepressant usage and elevated risks of CHD, CVD mortality and all-cause mortality. Further research is needed to assess whether the observed associations are causal, and elucidate the underlying mechanisms.

Publication and source details

Original title: Antidepressant use and risk of adverse outcomes: population-based cohort study

Narinder Bansal; Mohammed Hudda; Rupert A. Payne; Daniel J. Smith; David Kessler; Nicola Wiles

BJPsych Open · 2022

Correspondence: Dr Narinder Bansal. Email: narinder.bansal@bristol.ac.uk
*

Joint last authors.

© The Author(s) 20222022The Author(s)https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited. National Institute of Health Research School for Primary Care Research 422

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T22:33:24.399857+00:00

DOI: 10.1192/bjo.2022.563 · PMC9534882